Cat. No.: HY-W050154

Kojic acid

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Kojic acid is a substance produced by Aspergillus oryzae that is orally effective and can also be absorbed transdermally. Kojic acid exhibits various biological activities, including anti-aging, anti-nematode, antimicrobial, antioxidant, and anti-inflammatory effects. Kojic acid is a Tyrosinase inhibitor with an Mushroom Tyrosinase IC₅₀ of 182.7 μM. Kojic acid prevents melanin production by capturing copper ions that bind to the tyrosinase active site, thus inhibiting its activation. Kojic acid also suppresses the NF-κB and p21 signaling pathways in human keratinocytes. Kojic acid derivatives have anticancer activity.

For research use only. We do not sell to patients.

Purity: 99.99%
CAS No.: 501-30-4
Formula: C₆H₆O₄
Molecular Weight:142.11

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Kojic acid Chemical Structure

CAS No.: 501-30-4

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All Parasite Isoforms :

All NF-κB Isoforms :

All CDK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	GI₅₀	>100 μM Compound: 1; KA	Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35114540]
B16	IC₅₀	111 μM Compound: Kojic acid	Antimelanogenic activity in mouse B16 cells assessed as inhibition of intracellular melanin accumulation after 2 days Antimelanogenic activity in mouse B16 cells assessed as inhibition of intracellular melanin accumulation after 2 days	[PMID: 19524439]
B16	IC₅₀	61 μM Compound: Kojic acid	Inhibition of catecholase activity of tyrosinase in mouse B16 cells assessed as dopachrome formation Inhibition of catecholase activity of tyrosinase in mouse B16 cells assessed as dopachrome formation	[PMID: 19524439]
B16	IC₅₀	70 μM Compound: Kojic acid	Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 72 hrs Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 72 hrs	[PMID: 20044259]
B16	IC₅₀	70 μM Compound: kojic acid	Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 72 hrs Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 72 hrs	[PMID: 20097083]
B16	IC₅₀	>50 μM Compound: Kojic acid	Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 48 hrs Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 48 hrs	[PMID: 20149498]
B16	IC₅₀	70 μM Compound: Kojic acid	Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 3 days Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 3 days	[PMID: 21601449]
B16	IC₅₀	15.8 μM Compound: Kojic acid	Inhibition of alpha-MSH -stimulated melanogenesis in mouse B16 cells assessed as melanin release after 72 hrs by spectrometric analysis Inhibition of alpha-MSH -stimulated melanogenesis in mouse B16 cells assessed as melanin release after 72 hrs by spectrometric analysis	[PMID: 21978680]
B16	IC₅₀	70 μM Compound: Kojic acid	Antimelanogenic activity at alpha-MSH-stimulated mouse melanoma B16 cells after 3 days by spectrophotometry Antimelanogenic activity at alpha-MSH-stimulated mouse melanoma B16 cells after 3 days by spectrophotometry	[PMID: 22217872]
B16	IC₅₀	500 μM Compound: Kojic acid	Antimelanogenic activity in mouse B16 cells assessed as inhibition of melanogenesis Antimelanogenic activity in mouse B16 cells assessed as inhibition of melanogenesis	[PMID: 22300660]
B16	IC₅₀	5.5 μg/mL Compound: Kojic acid	Inhibition of alpha-MSH-stimulated melanogenesis in mouse B16 cells assessed as melanin release after 72 hrs Inhibition of alpha-MSH-stimulated melanogenesis in mouse B16 cells assessed as melanin release after 72 hrs	[PMID: 22450129]
B16	IC₅₀	39 μM Compound: Kojic acid	Inhibition of melanin production in alpha-MSH stimulated mouse B16 cells after 72 hrs by spectrophotometry Inhibition of melanin production in alpha-MSH stimulated mouse B16 cells after 72 hrs by spectrophotometry	[PMID: 23623417]
B16	IC₅₀	>500 μM Compound: Kojic acid	Inhibition of alpha-MSH-stimulated melanin production in mouse B16 cells after 72 hrs by microplate reader analysis Inhibition of alpha-MSH-stimulated melanin production in mouse B16 cells after 72 hrs by microplate reader analysis	[PMID: 26706112]
B16	IC₅₀	57 μM Compound: Kojic acid	Inhibition of alpha-MSH-stimulated melanogenesis in mouse B16 cells assessed as reduction in melanin formation Inhibition of alpha-MSH-stimulated melanogenesis in mouse B16 cells assessed as reduction in melanin formation	[PMID: 28619537]
B16-F10	IC₅₀	84.54 μM Compound: Kojic acid	Inhibition of alpha-MSH-induced melanogenesis in mouse B16F10 cells after 3 days by spectrophotometric analysis Inhibition of alpha-MSH-induced melanogenesis in mouse B16F10 cells after 3 days by spectrophotometric analysis	[PMID: 23063404]
B16-F10	IC₅₀	500 μM Compound: Kojic acid	Antimelanogenic activity in mouse B16F10 cells assessed as inhibition of melanin production after 4 days Antimelanogenic activity in mouse B16F10 cells assessed as inhibition of melanin production after 4 days	[PMID: 25597012]
B16-F10	IC₅₀	144.4 μM Compound: 1a; KA	Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability by MTT assay	[PMID: 32652434]
BV-2	IC₅₀	>500 μM Compound: KA	Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36846369]
G-361	IC₅₀	571.17 μM Compound: Kojic acid	Competitive inhibition of tyrosinase in human G-361 cells incubated for 10 mins measured for 2 hrs by MBTH-based spectrophotometry Competitive inhibition of tyrosinase in human G-361 cells incubated for 10 mins measured for 2 hrs by MBTH-based spectrophotometry	[PMID: 25288494]
H9c2	IC₅₀	>500 μM Compound: KA	Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36846369]
HEK293	IC₅₀	2 μM Compound: 6a, Kojic acid	Inhibition of human recombinant DAAO expressed in HEK293 cell lysate assessed as D-Serine conversion to H2O2 after 20 mins by spectrophotometric analysis Inhibition of human recombinant DAAO expressed in HEK293 cell lysate assessed as D-Serine conversion to H2O2 after 20 mins by spectrophotometric analysis	[PMID: 23683589]
HFF	IC₅₀	>150 μM Compound: 1a; KA	Cytotoxicity against human HFF cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HFF cells assessed as reduction in cell viability by MTT assay	[PMID: 32652434]
HT-22	IC₅₀	>500 μM Compound: KA	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36846369]
L02	IC₅₀	>500 μM Compound: KA	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36846369]
Melan-a	IC₅₀	1.6 mM Compound: 1	Depigmentation activity in mouse Melan-a cells assessed as inhibition of melanin formation after 4 days Depigmentation activity in mouse Melan-a cells assessed as inhibition of melanin formation after 4 days	[PMID: 22071299]
Melan-a	IC₅₀	3.5 mM Compound: 1	Cytotoxicity against mouse Melan-a cells by modified crystal voilet assay Cytotoxicity against mouse Melan-a cells by modified crystal voilet assay	[PMID: 22071299]
Melan-a	IC₅₀	1.46 μM Compound: 1, Kojic acid	Depigmenting activity in mouse Melan-a cells assessed as melanin production Depigmenting activity in mouse Melan-a cells assessed as melanin production	[PMID: 22330633]
Melan-a	IC₅₀	1.64 mM Compound: 1, Kojic acid	Depigmentation activity in mouse Melan-a cells after 4 days by spectrophotometry Depigmentation activity in mouse Melan-a cells after 4 days by spectrophotometry	[PMID: 22579419]
Melan-a	IC₅₀	3.53 mM Compound: 1, Kojic acid	Cytotoxicity against mouse Melan-a cells after 4 days by crystal voilet method Cytotoxicity against mouse Melan-a cells after 4 days by crystal voilet method	[PMID: 22579419]
MNT-1	CC₅₀	34 mM Compound: KA	Cytotoxicity against human MNT-1 cells Cytotoxicity against human MNT-1 cells	[PMID: 36462443]
MNT-1	IC₅₀	15 mM Compound: KA	Inhibition of melanogenesis in human MNT-1 cells incubated for 96 hrs Inhibition of melanogenesis in human MNT-1 cells incubated for 96 hrs	[PMID: 36462443]
MNT-1	CC₅₀	2200 μM Compound: Kojic acid	Cytotoxicity against human MNT-1 cells incubated for 14 days by resazurin assay Cytotoxicity against human MNT-1 cells incubated for 14 days by resazurin assay	[PMID: 38262119]
MNT-1	CC₅₀	22000 μM Compound: Kojic acid	Cytotoxicity against human MNT-1 cells incubated for 4 days by resazurin assay Cytotoxicity against human MNT-1 cells incubated for 4 days by resazurin assay	[PMID: 38262119]
MNT-1	IC₅₀	14000 μM Compound: Kojic acid	Inhibition of melanogenesis in human MNT-1 cells incubated for 4 days Inhibition of melanogenesis in human MNT-1 cells incubated for 4 days	[PMID: 38262119]
MNT-1	IC₅₀	800 μM Compound: Kojic acid	Inhibition of melanogenesis in human MNT-1 cells incubated for 14 days Inhibition of melanogenesis in human MNT-1 cells incubated for 14 days	[PMID: 38262119]
RAW264.7	IC₅₀	>100 μM Compound: 1	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 20934336]
RAW264.7	IC₅₀	89.41 μM Compound: 1	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated for 30 mins before LPS challenge measured after 24 hrs by Griess reagent method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated for 30 mins before LPS challenge measured after 24 hrs by Griess reagent method	[PMID: 20934336]
SH-SY5Y	IC₅₀	>500 μM Compound: KA	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36846369]

In Vitro

Kojic acid (1000 μM, 7 days) enhances the cell migration ability of HCEC cells and exhibits anti-aging activity^[1].
Kojic acid (1000 μM, 7 days) may alleviate the angiogenesis of human umbilical vein endothelial cells (HUVEC), induced by senescent supernatant of HCEC cells, through NF-κB and p21 signaling pathways^[1].
Kojic acid (1.4-1000 μg/mL, 3 days) exhibits dose-dependent mortality and hatch inhibition rates against Meloidogyne incognita, with EC50 values of 195.2 μg/mL and 238.3 μg/mL, respectively^[4].
Kojic acid (500 or 1000 µM, 72 h) reduces tyrosinase expression in B16-4A5 and HMV-II cells, indicating that kojic acid inhibits melanogenesis by suppressing tyrosinase activity^[6].
Kojic acid (10-2500 μM, 7 days) does not significantly affect the viability of HCEC cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HCEC-B4G12 cells (human corneal endothelial cell line)
Concentration:

10, 100 , 1000, 2500, 5000 μM
Incubation Time:

7 days
Result:

Did not influence the cell viability of HCEC after 7 days' treatment at 10-2500 μM but decreased the cell viability a little bit at 5000 μM.

Cell Migration Assay ^[1]

Cell Line:

HCEC-B4G12 cells (human corneal endothelial cell line)
Concentration:

1000 μM
Incubation Time:

7 days
Result:

Delayed the reduction in cell migration ability caused by aging in HCEC cells.

Western Blot Analysis^[1]

Cell Line:

HCEC-B4G12 cells (human corneal endothelial cell line)
Concentration:

1000 μM
Incubation Time:

7 days
Result:

Inhibited the abnormal high expression of galectin 8, laminin α1, laminin α2, laminin γ1, and p21 in senescent HCEC, as well as the significant decrease in p-NF-κB protein expression.

In Vivo

Kojic acid (50 mg/kg, p.o., once daily for 3 weeks) exhibits antioxidant and anti-inflammatory activities in a mouse model of Alzheimer's disease induced by β-Amyloid (1-42), human (HY-P1363A) ^[8].
Kojic acid (4, 6.4, 10, 16 g/kg, p.o., single dose) does not exhibit significant toxicity in acute oral studies in JCL-Wistar rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

β-Amyloid (1-42), human (HY-P1363A)-Induced Mouse Model of Alzheimer's Disease^[8]
Dosage:

50 mg/kg
Administration:

Oral gavage, once daily for 3 weeks
Result:

Ameliorated β-Amyloid (1-42), human (HY-P1363A)-induced glial cell activation and reduced inflammatory markers in the hippocampus.
Reduced ROS and lipid peroxidase levels in Alzheimer's Disease mice model

Animal Model:

JCL-Wistar rats^[2]
Dosage:

4, 6.4, 10, 16 g/kg
Administration:

Oral gavage (p.o.),single dose
Result:

Had an oral LD50 in rats greater than 2 g/kg in acute toxicity studies^[2].

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 501-30-4
Appearance Solid
Molecular Weight 142.11
Formula C₆H₆O₄
Color Off-white to light yellow
SMILES

O=C1C=C(CO)OC=C1O
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
Aspergillus, Penicillium or Acetobacter spp
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All WBIFRT-PCRCell Imaging/Staining

Sort by:

Journal Impact Factor

Int Immunopharmacol

Kojic acid alleviates osteoarthritis by attenuating inflammation and restoring impaired autophagy through regulating NF-κB and PI3K/AKT/mTOR signaling pathways: An in vivo and in vitro study. [Abstract]

2025 Jan 6:147:114022. PMID: 39764993

Kojic acid purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Jan 6:147:114022. [Abstract]

Kojic acid (KA) (5-20 μM; 24 h) significantly upregulated the expression levels of key anabolic factors, consisting of aggrecan, collagen II, as well as SOX9 in IL-1β-induced chondrocytes.

Kojic acid purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Jan 6:147:114022. [Abstract]

Kojic acid (KA) (20 μM; 24 h) reversed the dectrease in collagen II and aggrecan in IL-1β-induced chondrocytes.

Kojic acid purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Jan 6:147:114022. [Abstract]

Kojic acid (KA) (5-20 μM; 24 h) significantly inhibited the mRNA expression levels of iNOS, COX2, MMP13, and MMP3 in IL-1β-induced chondrocytes.

Kojic acid purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Jan 6:147:114022. [Abstract]

Kojic acid (KA) (20 μM; 24 h) downregulated protein expression levels of the phosphorylation of P65 and IκBα in IL-1β-induced chondrocytes.

Kojic acid purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Jan 6:147:114022. [Abstract]

Kojic acid (KA) (20 μM; 24 h) significantly increased autophagic flux in chondrocytes transfected with GFP-RFP-LC3 adenovirus.
Photochem Photobiol Sci

The extract of dendrobium Coelonin inhibits PIH induced by AFR CO2 fractional laser combined with UV-B. [Abstract]

2025 Oct;24(10):1763-1779. PMID: 41108468

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (703.68 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (351.84 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

7.0368 mL

35.1840 mL

70.3680 mL

5 mM

1.4074 mL

7.0368 mL

14.0736 mL

10 mM

0.7037 mL

3.5184 mL

7.0368 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 5 mg/mL (35.18 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (17.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (17.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 14.29 mg/mL (100.56 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wei X, et al. Kojic acid inhibits senescence of human corneal endothelial cells via NF-κB and p21 signaling pathways. Exp Eye Res. 2018 Dec 28;180:174-183. [Content Brief]

[2]. Burnett C L, et al. Final report of the safety assessment of kojic acid as used in cosmetics[J]. International journal of toxicology, 2010, 29(6_suppl): 244S-273S. [Content Brief]

[3]. Saeedi M, et al. Kojic acid applications in cosmetic and pharmaceutical preparations. Biomed Pharmacother. 2019 Feb;110:582-593. doi: 10.1016/j.biopha.2018.12.006. [Content Brief]

[4]. Kim T Y, et al. Nematicidal activity of kojic acid produced by Aspergillus oryzae against Meloidogyne incognita[J]. Journal of Microbiology and Biotechnology, 2016, 26(8): 1383-1391. [Content Brief]

[5]. Zilles J C, et al. Biological activities and safety data of kojic acid and its derivatives: A review[J]. Experimental dermatology, 2022, 31(10): 1500-1521. [Content Brief]

[6]. Kai H, et al. Assessment of the effect of arbutin isomers and kojic acid on melanin production, tyrosinase activity, and tyrosinase expression in B16-4A5 and HMV-II melanoma cells[J]. Planta Medica Letters, 2015, 2(01): e39-e41.

[7]. Karakaya G, et al. Synthesis and cytotoxic evaluation of kojic acid derivatives with inhibitory activity on melanogenesis in human melanoma cells[J]. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2018, 18(15): 2137-2148. [Content Brief]

[8]. Khan A, et al. Antioxidative and Anti-inflammatory Effects of Kojic Acid in Aβ-Induced Mouse Model of Alzheimer's Disease. Mol Neurobiol. 2021 Oct;58(10):5127-5140. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	7.0368 mL	35.1840 mL	70.3680 mL	175.9201 mL
	5 mM	1.4074 mL	7.0368 mL	14.0736 mL	35.1840 mL
	10 mM	0.7037 mL	3.5184 mL	7.0368 mL	17.5920 mL
	15 mM	0.4691 mL	2.3456 mL	4.6912 mL	11.7280 mL
	20 mM	0.3518 mL	1.7592 mL	3.5184 mL	8.7960 mL
	25 mM	0.2815 mL	1.4074 mL	2.8147 mL	7.0368 mL
	30 mM	0.2346 mL	1.1728 mL	2.3456 mL	5.8640 mL
	40 mM	0.1759 mL	0.8796 mL	1.7592 mL	4.3980 mL
	50 mM	0.1407 mL	0.7037 mL	1.4074 mL	3.5184 mL
	60 mM	0.1173 mL	0.5864 mL	1.1728 mL	2.9320 mL
	80 mM	0.0880 mL	0.4398 mL	0.8796 mL	2.1990 mL
	100 mM	0.0704 mL	0.3518 mL	0.7037 mL	1.7592 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Kojic acid

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Gut Microbial Metabolite Library

Anti-Blood Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Microbial Metabolite Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Fungal-Sourced Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Kojic acid

All Parasite Isoforms

All NF-κB Isoforms

All CDK Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs